RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis

Jul 21

Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, and Padron E. “RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis.” Cancer Discov. 2024 Aug 27.

doi: 10.1158/2159-8290.CD-24-0093 PMID: 39189614

Meghan Ferrall-Fairbanks

RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies

Development of an Automated Machine Learning-Driven Assay for Robust and Accessible Analysis of Cell Migration